Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
OPKO Health (NASDAQ:OPK) announced that subsidiary ModeX Therapeutics will present preclinical data on its MDX3001 candidate at the ASGCT 2026 Annual Meeting. Studies show in vivo CAR-T cell generation and deep systemic B-cell depletion in animal models using a CD3xCD28 antibody-conjugated LNP/mRNA platform.
OPKO Health (NASDAQ: OPK) amended its EirGen agreement with Nicoya Therapeutics to receive a 15% equity stake in Nicoya in exchange for a revised tiered royalty and transfer-price schedule, with the Series A-2 preferred share issuance closing in two tranches. The amendment expands RAYALDEE®'s Greater China field and preserves up to $115 million in milestone payments; RAYALDEE is approved in Macau and companies expect regulatory approvals in China and related territories in 2027.
BioReference (NASDAQ:OPK) launched BioReference Direct, a consumer-facing digital platform giving individuals direct online access to a menu of laboratory tests, backed by BioReference’s clinical labs and patient service centers.
The platform includes wellness panels, gender-specific tests and Abbott’s prescription-only simpli-COLLECT™ at‑home STI test with telehealth review and HIPAA-secure results delivery.
OPKO Health (NASDAQ: OPK) reported Q1 2026 results and business highlights on April 28, 2026. Consolidated revenue was $124.2 million and net loss was $54.8 million ($0.07/share). Cash and equivalents were $341.9 million as of March 31, 2026. Key pipeline updates include Phase 1 starts for MDX2301 (COVID-19 tetravalent bispecific) and MDX2003 (tetraspecific T-cell engager), ModeX in vivo CAR-T progress, and an expanded collaboration with Entera Bio targeting an IND filing in late 2026 for an oral long-acting PTH tablet. The company repurchased approximately $92.0 million of common stock since July 2025 with ~$108.0 million remaining authorized. Management provided Q2 and full-year 2026 guidance ranges.
OPKO Health (NASDAQ: OPK) subsidiary ModeX Therapeutics began dosing patients in a Phase 1 safety and tolerability study of MDX2003, a first‑in‑class tetraspecific T‑cell engager for relapsed or refractory B‑cell lymphoma, on April 22, 2026.
The drug targets CD19 and CD20 on tumor cells plus CD3 and CD28 on T cells; preclinical data and dose‑selection analyses were presented at ASH 2025 and ESMO TAT 2026.
OPKO Health (NASDAQ: OPK) will report first quarter 2026 operating and financial results for the period ended March 31, 2026 after market close on April 28, 2026.
Management will host a conference call and live audio webcast on April 28 at 4:30 p.m. Eastern to discuss results and financial guidance. Telephone replay and webcast replay will be available through early May.
ModeX Therapeutics (NASDAQ: OPK) initiated dosing in a Phase 1 trial of MDX2301, a tetravalent bispecific multispecific antibody designed to neutralize all known SARS-CoV-2 variants. The randomized, double-blind, placebo-controlled, dose-escalation study will assess safety and tolerability across intravenous, intramuscular and subcutaneous routes in up to 80 participants.
The trial is federally funded by HHS/ASPR/BARDA under contract 75A50123C00056 and will also evaluate pharmacokinetics, anti-drug antibodies and neutralizing activity.
OPKO Health (Nasdaq: OPK) will participate in the Jefferies Biotech on the Beach Summit March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will hold one-on-one investor meetings on Wednesday, March 11. Investors should contact their Jefferies representative to schedule meetings.
OPKO Health (NASDAQ: OPK) reported Q4 2025 results and 2026 guidance on Feb 26, 2026. Consolidated Q4 revenues were $148.5M vs $183.6M year-ago; Q4 net loss was $31.3M (‑$0.04 per share). Cash and equivalents were $369.1M at year-end. Key pipeline and partnerships: Regeneron multispecific collaboration (>$1B potential, >$200M program milestones), Merck EBV vaccine Phase 1 completed, BARDA-supported COVID antibody Phase 1 planned Q2 2026.
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and 12 months ended December 31, 2025, after U.S. markets close on February 26, 2026.
Senior management will host a business update, discuss results and provide financial guidance on a conference call and live webcast at 4:30 p.m. ET. Registration, dial-in numbers, webcast links and replay details are available for investors; telephone replay accessible through March 5, 2026.